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Aims: To evaluate the efﬁcacy and safety of adding a single bolus dose of insulin glulisine to
basal insulin (‘basal-plus’) in persons with type 2 diabetes.
Methods:Data frompatientswith poor glycemic control on oral antihyperglycemic drugswho
were initiated on a ‘basal-plus’ regimen for up to 6 months were pooled from four random-
ized, multicenter studies. Glycated hemoglobin (HbA1c), fasting blood glucose, postprandial
glucose (PPG), insulin dose and demographics were measured at baseline and end of study.
Results: 711 patients with a mean age of 59.9 years and a mean duration of diabetes of 11.0
years were included in the analysis population. A ‘basal-plus’ regimen was associated with
signiﬁcant decreases in HbA1c and PPG at 6 months, an increase in glargine and glulisine
doses and small, but statistically signiﬁcant, changes in body weight and BMI in all patient
subsets. The proportion of patients with HbA1c<7% also increased in all populations stud-
ied, while the prevalence of severe hypoglycemia was low and did not signiﬁcantly differ
across patient groups.Conclusions: These results suggest that the use of ‘basal-plus’ can achieve a good therapeutic
response with a low risk of hypoglycemia and weight gain, regardless of a patient’s age or
BMI.
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1. Introduction
Type 2 diabetes (T2D) is a chronic disease characterized by
a progressive decline of -cell function and/or mass in the
presence of insulin resistance that requires timely treatment
intensiﬁcation to achieve and maintain optimum metabolic
control [1]. Currently, basal insulin represents the simplest
and most effective method for controlling fasting hyper-
glycemia [2,3]. Nonetheless, only approximately half of all
patients achieve target glycated hemoglobin (HbA1c) goals
despite adequate dose titration and the achievement of near
normoglycemia, thus indicating a need for additional treat-
ment to control postprandial glucose (PPG) excursions [4,5].
This can be achieved using different therapeutic modalities,
including (1) a ﬁxed combination of a rapid-acting insulin
analog (RAA) and an intermediate-acting insulin, i.e., pre-
mixed insulins; (2) a combination of a basal insulin and a
glucagon-like peptide-1 (GLP-1) receptor agonist; and (3) a
‘basal-bolus’ regimen, i.e., administration of a RAA to ongoing
basal insulin before each meal. More recently, a ‘basal-plus’
stepwise treatment regimen, i.e., a single injection of pran-
dial insulin prior to the meal associated with the largest
PPG excursion, has been proposed. Several clinical trials have
demonstrated the efﬁcacy and safety of adding single bolus
doses of insulin glulisine to basal insulin glargine [6–11]; how-
ever, the effect of individual factors such as a patient’s age or
BMI on the efﬁcacy of this treatment strategy has yet to be
clariﬁed.
Therefore, a retrospective analysis of previous studies was
performed to evaluate both the efﬁcacy and safety of adding
a single bolus of the ‘basal-plus’ regimen in patients with T2D
when stratiﬁed by age and BMI.
2. Methods
2.1. Study design and patient population
Patient-level data were pooled retrospectively from four
randomized, controlled, multicenter parallel-group studies
designed to evaluate the efﬁcacy and safety of a ‘basal-
plus’ regimen in patients with T2D (OPAL [NCT00272012],
ELEONOR [NCT00272064], 1-2-3 [NCT00135083], and a proof-
of-concept study [NCT00360698]) [9,12–14]. Participants aged
≥ 18 years who had a diagnosis of T2D and who were poorly
controlled (HbA1c≥ 6.5% or 48mmol/mol) using basal insulin
glargine in addition to oral antidiabetic agents (OADs), with
both baseline and end of study HbA1c and BMI measure-
ments available, were deemed eligible for inclusion in this
pooled study population. All included patients were initiated
on a basal insulin glargine in addition to OADs, to which
insulin glulisine was subsequently added once daily (‘basal-
plus’ approach) for up to 6 months. Insulin glargine was
titrated to protocol-deﬁned fasting blood glucose (FBG) tar-
gets (with the exception of one study [13] in which no titration
was undertaken), while insulin glulisine was introduced and
dose titrated to protocol-deﬁned preprandial or PPG targets
[9,12–14].s 1 0 ( 2 0 1 6 ) 51–59
2.2. Outcomes and clinical end of studies
Demographic and clinical characteristics (gender, age, weight,
height, BMI, duration of diabetes and age at ﬁrst diagnosis
of diabetes) as well as antidiabetic drug usage (duration of
prior OAD and/or insulin use, age at initiation of OAD and/or
insulin use and insulin glulisine administration time) were
collected and analyzed. Efﬁcacy of the ‘basal-plus’ insulin reg-
imenwas determined from the insulin dose and the (1) change
of HbA1c levels from baseline and proportion of patients
achieving HbA1c<7% (< 53.0mmol/mol); (2) change of FBG
level from baseline and proportion of patients at < 110mg/dL
(< 6.1mmol/L); (3) change of PPG levels from baseline and
proportion of patients at < 180mg/dL (< 10.0mmol/L); and (4)
change of weight and BMI over the study periods.
Safetymeasurements comprised the frequency of episodes
of severe hypoglycemia, nocturnal hypoglycemia and symp-
tomatic hypoglycemia (as deﬁned in each trial anddetermined
from data collected during the respective trials [Appendix])
[9,12–14].
Efﬁcacy and safety measurements were then analyzed fol-
lowing stratiﬁcation by age (< 55, 55–64 and≥ 65 years) andBMI
(< 30, 30–35 and ≥ 35kg/m2).
2.3. Statistical analyses
Due to the requirement for HbA1c and BMI data at baseline
and at end of study, the total available number of patients
was reduced (hereafter referred to as the ‘analysis popula-
tion’) (Table A1) [9,12–14]. A patient-level meta-analysis was
conducted to allow for study-to-study differences. Descrip-
tive statistics were used to measure and describe clinical
characteristics and patient demographics as well as efﬁcacy
and safety outcome measurements. p values, unadjusted for
study origin, were provided by 2 test or analysis of variance
(ANOVA) when appropriate. Baseline and end of study efﬁcacy
measurements were compared with p values calculated using
paired t-tests; a p value <0.05 was used to determine the level
of statistical signiﬁcance, again unadjusted for study origin.
A generalized linear model was used to assess the differ-
ence between end of study and baseline measurements for
HbA1c, weight and BMI while adjusting for patient age, gen-
der, duration of diabetes and different studies. A multivariate
logistic regression model was used to assess the impact of
patient characteristics on the risk of hypoglycemia.
The outcomeswere combined across studies using the ran-
domeffectsmeta-analysis approachofDerSimonianandLaird
[15]. All statistical analyses were carried out using SAS® ver-
sion 9.3 (SAS Institute Inc., Cary, NC).
3. Results
3.1. Baseline characteristics
A total of 711 patients comprised the analysis patient popu-
lation; 53.3% were male, mean age 59.9± 9.5 years, and the
mean known duration of T2D was 11.0± 7.0 years (Table 1).
Prior to the study periods the mean duration of OAD use was
6.5± 5.7 years and the mean duration of basal insulin use
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was 2.2± 2.2 years (Table 1). The mean age at ﬁrst OAD and
insulin usage was 53.5± 9.7 years and 60.6± 9.2 years, respec-
tively. Themajority of patients received an injection of insulin
glulisine at dinner time (41.3%); of the remaining patients,
35.8% and 22.9% received their dose prior to breakfast and
lunch, respectively. The majority of patients were receiving
either metformin (77.7%) or sulfonylureas (69.0%) at baseline,
with smaller numbers receiving thiazolidinediones, glinides,
or other OADs.
At baseline and study endpoint the mean dose of insulin
glulisinewas 4.91U and 13.21U, respectively; themean insulin
glargine dose was 36.78U and 41.91U, respectively.
The mean dose/weight of insulin glulisine was 0.06U/kg
and 0.14U/kg, respectively; the mean insulin glargine dose
was 0.40U/kg and 0.45U/kg, respectively.
For the subanalyses of patients by age (< 55, 55–64 and
≥ 65 years) and BMI (< 30, 30–34 and ≥ 35kg/m2), a total of
711 patients were included. In general, baseline demograph-
ics and clinical characteristics were essentially similar across
the two cohorts. However, there were signiﬁcant differences
within the two subgroups according to weight, BMI, duration
of diabetes and age at ﬁrst diagnosis (Table 1).
3.2. Analysis population
The addition of a single injection of insulin glulisine at the
main meal in patients already receiving an existing therapy
of OADs and once-daily basal insulin resulted in signiﬁcant
decreases (mean±SD) inHbA1c of−0.4± 0.1% (p<0.0001), FBG
2.8± 3.7mg/dL (p=0.05) and PPG −58.9± 9.1mg/dL (p<0.0001)
over a 6-month follow-up. These ﬁndings were conﬁrmed
in a meta-analysis of changes in HbA1c, FBG and PPG
(Table 2).
Furthermore, after 6 months of ‘basal-plus’ insulin ther-
apy, more than twice as many patients achieved target HbA1c
levels (< 7% [< 53.0mmol/mol]) at end of study compared with
baseline (45.3% vs. 20.3%, p<0.001) (Fig. 1). Also, amuch higher
proportion of patients (80.4% vs. 40.5%, p<0.001) achieved tar-
get PPG levels (< 180mg/dL [< 10.0mmol/L]), while there were
no differences in the proportion of patients achieving tar-
get FBG at end of study compared with baseline (< 110mg/dL
[< 6.1mmol/L]; 40.0% vs. 44.4%).
Both overall daily doses (U) of basal insulin glargine and
insulin glulisine increased from baseline to end of study
(+6.9U to ±15.4 [p<0.0001] and +8.4U to ±10.4 [p<0.0001],
respectively). Similar results were observed when insulin
doses were expressed per kg body weight (U/kg; +0.07 to ±0.14
[p<0.0001] and +0.05 to ±0.22 [p<0.0001]), respectively). A
small, though statistically signiﬁcant (p<0.0001), increase in
body weight (+0.9 to ±4.0 kg) and BMI (+0.3 ±1.4 kg/m2) was
observed.
In the analysis population, 1.7%, 12.4% and 37.9% of
patients experienced a severe, nocturnal or symptomatic
hypoglycemia event (as deﬁned in each study protocol),
respectively. The mean number of events per year for severe,
nocturnal or symptomatic hypoglycemia was 0.03 (±0.2), 0.6
(±2.3) and 4.7 (±11.4), respectively (Fig. 2A). Nearly half the
population (44.3%) achieved target HbA1c goals without expe-
riencing severe or symptomatic hypoglycemia (43.0%).
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No predictors for an increased risk of severe hypoglycemia
could be identiﬁed. When nocturnal hypoglycemia was con-
sidered, both female gender (odds ratio [OR] 1.81; p<0.05)
and diabetes duration (OR 1.06; p<0.01) emerged as risk pre-
dictors. Moreover, insulin glargine dose (OR 1.02; p<0.0001),
female gender (OR 1.92; p<0.001) and diabetes duration (OR
1.04; p<0.01) were risk factors for symptomatic hypoglycemia.
The forest plots (Fig. 3) from the meta-analyses show
changes from baseline to end of study, demonstrating that
HbA1c decreased, while weight and BMI increased slightly.
3.3. Age cohort
Table 1 illustrates the characteristics of the study population
stratiﬁed according to age. Both BMI and FPG declined across
the three age categories, whereas age at diagnosis and dia-
betes duration increased. Therewerenodifferences forHbA1c.
The ‘basal-plus’ regimen resulted in signiﬁcant (p<0.001)
reductions in mean HbA1c and PPG within each of the three
age groups, with the smallest reduction in HbA1c occurring
in the younger age group (Table 2). Conversely, there was an
increase inmean FBG from baseline to end of study in all three
age groups (Table 2), with a signiﬁcant change in the <55 years
age group compared with the other age groups (p<0.05).
Fig. 1 shows the proportion of patients atHbA1c target (< 7%
[< 53.0mmol/mol]) at baseline and 6 months after initiation
of the ‘basal-plus’ regimen. A greater proportion of patients
achieved HbA1c target at end of study comparedwith baseline
in all age groups; however, in patients aged ≥ 65 years, the dif-
ference from baseline to end of study was less pronounced.
Doses of insulin glargine and insulin glulisine increased in
all age groups (p<0.0001), with the highest dose increases
observed in the younger (< 55 years) patients (10.5U and 10.7U,
respectively).
There were small but signiﬁcant (p<0.05) increases in both
weight and BMI in all three age groups from baseline to end
of study, with the magnitude of the weight and BMI gain
markedly lower in the older (55–64 and ≥ 65 years) age groups
(Table 2).
In the three age groups (< 55, 55–64 and ≥ 65 years), 2.0%,
0.8% and 2.3% of patients experienced a severe hypoglycemic
event (as deﬁned in each study protocol), respectively. There
was no signiﬁcant difference between the three subgroups in
the incidence of severe or symptomatic hypoglycemic events;
however, there were more nocturnal hypoglycemic events in
the two older age groups (p<0.05) (Fig. 2B).
3.4. BMI cohort
There were no signiﬁcant differences between the BMI sub-
groupswith respect to change inHbA1c, FBG and PPG (Table 2).
For both HbA1c and PPG, the observed decreases were signif-
icant in all three BMI groups (p<0.001). An increase in FBG
levels was apparent in all three subgroups, which reached
signiﬁcance only in the BMI <30kg/m2 group (p<0.001).
As compared with baseline, the ‘basal-plus’ regimen was
associated with an increased proportion of patients achieving
target HbA1c levels (< 7% [< 53.0mmol/mol]), which was more
apparent in patientswith a higher BMI (Fig. 1). Similar ﬁndings
were observed with respect to FBG and PPG levels.
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FFig. 1 – Proportion of patients achieving ta
Both basal insulin glargine and insulin glulisine doses
ncreased (p<0.0001) from baseline to end of study in all three
MI subgroups, with the highest dose increases observed for
he ≥ 35kg/m2 group (both 12.3U).
Over the duration of the study, there were small but signif-
cant (p<0.05) increases in both weight and BMI within each
MI group, with no signiﬁcant differences between the three
ubgroups (Table 2).
ig. 2 – Incidence of hypoglycemic events per year in the (A) anaHbA1c goals at baseline and end of study.
The percentage of patients experiencing hypoglycemia
was generally low in the three BMI groups (< 30, 30–34 and
≥ 35kg/m2) at 2.5%, 1.8% and 0.0%, respectively, and virtu-
ally absent in those with the highest BMI. In particular, there
were no signiﬁcant differences between the three subgroups
in the incidence (events per year) of severe or nocturnal
hypoglycemia. However, there were signiﬁcant differences
in the number of symptomatic hypoglycemic events, with
lysis population, (B) age cohort and (C) BMI study cohort.
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Fig. 3 – Meta-analysis of (A) HbA1c (%), (B) weight change (kg) and (C) BMI change (kg/m2) of study populations treated with
‘basal-plus’ insulin regimen. Meta-analysis with random effect model was used for the analysis; meta-analysis has been
performed on unadjusted mean changes, without interaction terms (DerSimonian & Laird method) [15]. p value for
heterogeneity: p<0.0001.
the highest events rate observed in the ≥ 35kg/m2 group
(Fig. 2C).
4. Discussion
The ﬁndings of this analysis demonstrate that a ‘basal-plus’
regimen with insulin glulisine added to basal insulin glargine
is effective and well tolerated in patients with T2D who are
poorly controlled on basal insulin with/without OADs. Inter-
estingly, individual factors such as a patient’s age or BMI
appear to have only a minimal impact on these outcomes.
As expected in this analysis of patients treated with a
‘basal-plus’ regimen, signiﬁcant reductions in HbA1c, FBG and
PPGwere observed at end of study for the analysis population.
However, while there were reductions in both HbA1c and PPG
for patients stratiﬁed by both age and BMI, FBG was seen to
increase in both patient populations. Interestingly, when we
consider the individual data from each study, it is apparent
that there is considerable heterogeneity across all four studies.
Notably, we observed that there was a large increase in FBG in
the OPAL study [13] compared with relatively small increases
(or reductions) in the other three studies analyzed (Table A1).
As the OPAL study comprised more than 40% of the analysis
population, and no glargine titration was undertaken in this
study, this unexpected ﬁnding appears to be driven by the data
from this study alone.
A higher proportion of patients achieved target HbA1c lev-
els (< 7% [< 53.0mmol/mol]) at end of study compared with
baseline. Whilst HbA1c may be affected by other factors than
insulin, i.e., diet, physical activity, and other hypoglycemic
agents, it was interesting to note that, with increasing age
and BMI, fewer patients achieved target HbA1c goals at end
of study (compared with baseline) when using this regimen.
In addition to HbA1c, FBG and PPG changes, the overall daily
doses of basal insulin and glulisine increased signiﬁcantly
from baseline to end of study in all patient populations, with
the greatest increases seen in the younger age groups and
those with the highest initial BMI.While there were also small
increases in body weight (and BMI) for all patient popula-
tions observed, the least weight gain was seen in the oldest
age group (≥ 65 years). Interestingly, weight gain has beencorrelated directly with insulin dose [16] which, as previously
described, was lowest in the oldest patient subgroup. Over-
all, there was a low prevalence of hypoglycemia, including
severe hypoglycemia, for all patient populations, with no sig-
niﬁcant differences between patients stratiﬁed by age or BMI.
A low incidence of hypoglycemia has been associated with a
reduced propensity for snacking [17,18], which may have pos-
itively contributed to the low levels of weight gain observed in
this study.
The meta-analysis (Fig. 3) gives us a further means by
which to assess the between-study variation in the results,
as well as providing an overall estimate of effect. These ﬁnd-
ings conﬁrm that while HbA1c decreased, weight and BMI
increased slightly.
We acknowledge that there are a number of limitations
associated with our meta-analysis, including publication bias
(i.e., selection of speciﬁc results for publication), use of differ-
ent study designs and data collection methods and lack of a
comparator or placebo group. As described above, the consid-
erable heterogeneity observed across all four studies included
in this pooled analysis (Table A1) may have inﬂuenced the
overall ﬁndings. Nevertheless, despite these limitations, the
results of this study have shown that a ‘basal-plus’ approach
using a RAA such as insulin glulisine in addition to basal
insulin glargine is still a relevant option for many patients,
even considering the availability of new GLP-1 mimetics.
5. Conclusions
The use of ‘basal-plus’ as an initial stepwise insulin treatment
regimen, involving a single preprandial injection of insulin
glulisine (on a background of basal insulin glargine) given
before the meal associated with the largest PPG excursion,
can achieve a good therapeutic response with a low risk of
hypoglycemia and weight gain, regardless of the patient’s age
or BMI. The ﬁndings of our analysis demonstrate the efﬁcacy
and safety of a ‘basal-plus’ regimen in the different patient
subsets studied, and provide clinicians with a relevant, alter-
native therapeutic option in this difﬁcult-to-treat population
with T2D. Future studies, comparing a ‘basal-plus’ treatment
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Table A1 – Individual studies comprising the meta-analyses.
Study Study period
(treatment
duration)
Study
population
Treatment (ITT
population)
Primary
analysis
Analysis
population
ﬁndings (N=711)
OPAL study
(3507),
Lankisch, et al.
[13]
June 2004 to
September 2006 (24
weeks)
Aged≥ 18 years,
prior treatment with
insulin glargine and
OADs (excluding
-glucosidase
inhibitors) ≥ 3
months, A1c 6.5–9%,
FBG ≤ 120mg/dL
393 patients
(insulin glulisine
at breakfast
[n=196], insulin
glulisine at main
meal [n=197])
To investigate
whether the
addition of a
single bolus of
insulin glulisine,
administered at
either breakfast
or main
mealtime, in
combination
with basal
insulin glargine
and OADs,
provides
equivalent
glycemic control
in patients with
T2D, irrespective
of the time of
glulisine
injection
HbA1c
n=315
Mean change
(SE) = –0.3 (0.0)
FBG
n=261
Mean change
(SE) = 10.3 (1.5)
PPG
n=298
Mean change
(SE) = –44.3 (2.9)
ELEONOR study
(3514), Del
Prato, et al. [9]
October 2005 to May
2008 (24 weeks)
Aged 35–70 years,
prior treatment with
combined OADs or
maximal dose
metformin ≥ 3
months, A1c
7.5–11%, BMI
>25kg/m2
241 patients
(telecare [n=115],
common SMBG
[n=126])
To compare the
change in HbA1c
from baseline
(visit 3) with end
of treatment
phase (visit 5) for
patients in the
telecare and
SMBG programs
HbA1c
n=241
Mean change
(SE) = –0.7 (0.1)
FBG
n=237
Mean change
(SE) = 0.4 (2.9)
PPG
n=186
Mean change
(SE) = –67.4 (3.9)
1-2-3 study
(3511),
Davidson, et al.
[12]
August 2004 to
November 2007
(24 weeks)
Aged 18–79 years,
T2D≥ 6 months,
current treatment
with two or three
OADs from three
therapeutic classes,
HbA1c ≥ 8%, fasting
C-peptide
concentration >0.27
nmol/L
Insulin glargine
plus insulin
glulisine
administered
once a day
(n=115), twice a
day (n=113),
three times a day
(n=115)
To demonstrate
noninferiority in
the change in
glycemic control
as measured by
HbA1c
HbA1c
n=107
Mean change
(SE) = –0.4 (0.1)
FBG
n=94
Mean change
(SE) = –4.3 (6.7)
PPG (not evaluated)
Proof-of-concept
study (4002),
Owens, et al.
[14]
June 2006 to August
2008 (24 weeks)
Aged 18–75 years,
prior treatment with
basal insulin and at
least 1 g metformin
daily for ≥ 3 months,
HbA1c 7.5–9.5%, BMI
25–45kg/m2
106 patients
(insulin glulisine
at main meal
[n=49], control
[no insulin
glulisine, n=57])
To evaluate the
proportion of
patients
achieving HbA1c
<7.0% at end of
study
HbA1c
n=48
Mean change
(SE) = –0.4 (0.1)
FBG
n=46
Mean change
(SE) = 1.0 (4.9)
PPG
n=45
Mean change
(SE) = –66.3 (8.1)
FBG, fasting blood glucose; HbA1c, glycated hemoglobin; ITT, intent-to-treat; OAD, oral antidiabetic drug; T2D, type 2 diabetes; SMBG, self-
monitoring of blood glucose.
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regimen with newer treatment options, such as the GLP-1
mimetics, may be of interest.
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Appendix A
Table A1.
A.1. Deﬁnitions of hypoglycemia
• Symptomatic hypoglycemia was deﬁned as follows:
o OPAL Study (3507), Lankisch, et al. [13]: An event with
characteristic symptoms consistent with hypoglycemia,
or asymptomatic if no symptoms occurred but was con-
ﬁrmed by blood glucose levels ≤ 60mg/dL.
o 1-2-3 Study (3511), Davidson, et al. [12]: An event
with symptoms consistent with hypoglycemia and a
self-measured blood glucose (SMBG) level ≥ 36mg/dL
(≥ 2.0mmol/L) but < 70mg/dL.
o Proof-of-Concept Study (4002), Owens, et al. [14]: An event
with clinical symptoms that were considered to result
from hypoglycemia (conﬁrmed or not by a blood glucose
measurement) andassociatedwithprompt recovery after
oral carbohydrate administration.
• Severe hypoglycemia was deﬁned as follows:
o OPAL Study (3507), Lankisch, et al. [13]: An event associ-
ated with a blood glucose level < 36mg/dL (2.0mmol/L)s 1 0 ( 2 0 1 6 ) 51–59
and/or an administration of oral carbohydrate or intra-
venous glucose or glucagons, with symptoms consistent
withhypoglycemia, duringwhich theperson required the
assistance of another person.
o 1-2-3 Study (3511), Davidson, et al. [12]: An event with
symptoms consistent with hypoglycemia in which the
assistance of another party was required (not merely
requested) and either (A) a recorded SMBG of < 36 mg/dL
(< 2.0mmol/L), or (B) there was treatment with oral car-
bohydrates, intravenous glucose or glucagon, and there
was prompt response to that therapy.
o Trial 3514: An event associated with a blood glucose
level < 36mg/dL (2.0mmol/L) and/or with prompt recov-
ery after oral carbohydrate or intravenous glucose or
glucagons, with clinical symptoms that were consid-
ered to result from hypoglycemia, in which the person
required the assistance of another person.
• Nocturnal hypoglycemia was deﬁned as an event with
clinical symptoms that were considered to result from
hypoglycemia that occurred while the patient was asleep,
between bedtime and getting up in the morning.
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